- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03499691
Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration
February 17, 2022 updated by: Baxter Healthcare Corporation
An Open-label, Prospective, Randomized, Parallel-Group, Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration
Today it is well established that middle molecules comprise several compounds that are not effectively removed by high-flux dialyzers, and effective clearance of large middle molecules in the process of dialysis depends on the dialyzer membrane having large enough pore sizes, larger than the conventional high-flux dialyzers.
Studies have found associations between levels of large middle molecule uremic toxins and immune dysfunction and inflammation, as well as adverse outcomes.
This indicates that dialysis membranes having larger pores, enabling an expanded HD (HDx) with more effective removal of large middle molecules, can have a positive impact on the inflammatory state.
While data is starting to appear on the long-term use of the HDx therapy, little is still known on how large middle molecules and inflammation markers are affected over time.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Murcia, Spain
- RTS Murcia VII, RTS Servicios de Diálisis S.L.U.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ESRD patients age between 18 - 80 years
- Clinically stable as judged by the treating physician for 30 days prior to enrollment, as demonstrated by pertinent patient medical history, physical examination, and laboratory testing
- Hemodialysis therapy with HDF for at least 3 months immediately prior to study enrollment
Exclusion Criteria:
- No informed consent provided
- Significant psychiatric disorder, mental disability, or other condition that may interfere with the patient's ability to provide informed consent
- Pregnant, breastfeeding, or planning to become pregnant
- Unstable vascular access associated with risk of low and variable extracorporeal blood flow rate (QB)
- Chronic liver disease, known paraprotein-associated disease, known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia and active peptic ulcers)
- Major bleeding episode (i.e. soft tissue bleeding, blood in stool, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to enrollment
- Blood (red blood cell) transfusion ≤ 12 weeks prior to enrollment
- Clinical signs of acute infection ≤ 4 weeks prior to enrollment
- Active cancer, except for basal cell or squamous cell skin cancer
- Positive serology test for human immunodeficiency virus or hepatitis infection
- Scheduled for planned interventions requiring hospitalization > 1 week
- Scheduled for living-donor transplantation within the study period
- Currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months that may interfere with this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Expanded Hemodialysis (HDx) Therapy
Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
|
The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period.
However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment.
If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer.
However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
|
Active Comparator: Hemodiafiltration (HDF) Therapy
Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
|
The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Reduction ratios of lambda immunoglobulin free light chains (λ-FLC)
Time Frame: Week 12
|
Week 12
|
Reduction ratios of kappa immunoglobulin free light chains (k-FLC)
Time Frame: Week 12
|
Week 12
|
Reduction ratios of chitinase-3-like protein 1 (YKL-40)
Time Frame: Week 12
|
Week 12
|
Reduction ratios of fibroblast growth factor 23 (FGF-23)
Time Frame: Week 12
|
Week 12
|
Reduction ratios of serum beta-2 microglobulin (β2M)
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in mid-week pre-dialysis serum levels of λ-FLC, κ-FLC, YKL-40, FGF-23, ß2M
Time Frame: Week 12 and 24
|
Week 12 and 24
|
Change from baseline in mid-week pre-dialysis serum levels of pentraxin-3 (PTX-3), high sensitivity C-reactive protein (hs-CRP), interleukin (IL-6), and interleukin-10 (IL-10)
Time Frame: Week 12 and 24
|
Week 12 and 24
|
Percent change from pre- to post-dialysis in mid-week serum levels of hs-CRP
Time Frame: Week 12
|
Week 12
|
Percent change from pre- to post-dialysis in mid-week serum levels of PTX-3
Time Frame: Week 12
|
Week 12
|
Percent change from pre- to post-dialysis in mid-week serum levels of IL-6
Time Frame: Week 12
|
Week 12
|
Percent change from pre- to post-dialysis in mid-week serum levels of IL-10
Time Frame: Week 12
|
Week 12
|
Change from baseline in mid-week pre-dialysis serum level of fibrinogen
Time Frame: Week 12 and 24
|
Week 12 and 24
|
Change from baseline in mid-week pre-dialysis serum level of albumin
Time Frame: Week 12 and 24
|
Week 12 and 24
|
Single pool Kt/Vurea
Time Frame: Week 24
|
Week 24
|
Serum phosphorous
Time Frame: Week 24
|
Week 24
|
Kidney Disease Quality of Life 36 (KDQOL-36)
Time Frame: Baseline, Week 12, Week 24
|
Baseline, Week 12, Week 24
|
Dialysis Symptom Index (DSI)
Time Frame: Baseline, Week 12, Week 24
|
Baseline, Week 12, Week 24
|
Serum ferritin
Time Frame: Baseline, Week 12, Week 24
|
Baseline, Week 12, Week 24
|
Transferrin Saturation (TSAT)
Time Frame: Baseline, Week 12, Week 24
|
Baseline, Week 12, Week 24
|
24-hour urine output on monthly basis
Time Frame: Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
|
Month 1, Month 2, Month 3, Month 4, Month 5, Month 6
|
Erythropoiesis stimulating agent (ESA) responsiveness
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Hemoglobin levels
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
ESA dosage by type, administration frequency, and route
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Intravenous iron dosage
Time Frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
|
Number of adverse events of hospitalization, cardiovascular events, and infective episodes
Time Frame: Week 1 through Week 24
|
Week 1 through Week 24
|
Total patient death
Time Frame: Week 1 through Week 24
|
Week 1 through Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Baxter Clinical Trials, Baxter Healthcare
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 11, 2018
Primary Completion (Actual)
October 4, 2018
Study Completion (Actual)
October 4, 2018
Study Registration Dates
First Submitted
April 9, 2018
First Submitted That Met QC Criteria
April 13, 2018
First Posted (Actual)
April 17, 2018
Study Record Updates
Last Update Posted (Actual)
February 23, 2022
Last Update Submitted That Met QC Criteria
February 17, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BXU012191
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Theranova 500 medium cut-off dialyzer
-
Technical University of MunichUnknownCardiovascular Diseases | End Stage Renal DiseaseGermany
-
Gangnam Severance HospitalCompletedChronic Kidney Disease Requiring Chronic DialysisKorea, Republic of
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
Carlo Maria GuastoniUnknown
-
Baxter Healthcare CorporationCompletedEnd Stage Renal DiseaseUnited States
-
Réseau de Santé Vitalité Health NetworkUnknownEnd Stage Renal Disease on DialysisCanada
-
Poitiers University HospitalBaxter Healthcare CorporationCompletedEnd Stage Renal Disease | Dialysis Related Complication | Dialysis AmyloidosisFrance
-
Fundación SenefroUnknownChronic Kidney Disease Requiring Chronic DialysisSpain
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHCompletedEnd-Stage Renal Disease (ESRD)Italy
-
Manchester University NHS Foundation TrustBaxter Healthcare Corporation; Manchester Metropolitan UniversityCompletedCardiovascular Diseases | Inflammation | End Stage Renal DiseaseUnited Kingdom